Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Private Management Group Inc.

Private Management Group Inc. lowered its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.1% in the fourth quarter, HoldingsChannel.com reports. The firm owned 1,517,438 shares of the company’s stock after selling 98,730 shares during the quarter. Private Management Group Inc.’s holdings in Teva Pharmaceutical Industries were worth $15,842,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Element Wealth LLC lifted its position in Teva Pharmaceutical Industries by 394.8% in the fourth quarter. Element Wealth LLC now owns 65,740 shares of the company’s stock valued at $686,000 after acquiring an additional 52,454 shares during the last quarter. Duality Advisers LP purchased a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at $1,621,000. abrdn plc lifted its position in Teva Pharmaceutical Industries by 713.5% in the fourth quarter. abrdn plc now owns 511,986 shares of the company’s stock valued at $5,345,000 after acquiring an additional 449,053 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its position in Teva Pharmaceutical Industries by 6.9% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 28,919,540 shares of the company’s stock valued at $301,920,000 after acquiring an additional 1,860,000 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Teva Pharmaceutical Industries by 2.9% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 424,280 shares of the company’s stock valued at $4,429,000 after acquiring an additional 12,003 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 100,000 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the transaction, the executive vice president now directly owns 382,590 shares in the company, valued at $5,172,616.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CAO Amir Weiss sold 31,766 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $12.37, for a total value of $392,945.42. Following the sale, the chief accounting officer now directly owns 10,676 shares in the company, valued at $132,062.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Mark Sabag sold 100,000 shares of the stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the sale, the executive vice president now owns 382,590 shares in the company, valued at $5,172,616.80. The disclosure for this sale can be found here. Insiders sold 390,738 shares of company stock valued at $5,132,766 over the last ninety days. Corporate insiders own 0.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Piper Sandler raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $12.00 to $19.00 in a research report on Monday, February 12th. The Goldman Sachs Group upped their target price on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a report on Monday, February 5th. Jefferies Financial Group raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and upped their target price for the company from $10.00 to $14.00 in a report on Tuesday, January 23rd. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 1st. Finally, JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price for the company in a report on Friday, March 8th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $13.78.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA traded up $0.13 during trading hours on Tuesday, hitting $13.01. 8,981,770 shares of the stock were exchanged, compared to its average volume of 10,621,822. The company has a market cap of $14.59 billion, a price-to-earnings ratio of -27.68, a price-to-earnings-growth ratio of 1.54 and a beta of 1.05. Teva Pharmaceutical Industries Limited has a 12-month low of $7.09 and a 12-month high of $14.47. The stock has a 50-day moving average of $13.50 and a 200 day moving average of $11.33. The company has a quick ratio of 0.69, a current ratio of 1.02 and a debt-to-equity ratio of 2.23.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 31st. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.25. The firm had revenue of $4.46 billion during the quarter, compared to analysts’ expectations of $3.97 billion. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. As a group, equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.28 earnings per share for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.